HELICOVAXORProject reference: 315640
Funded under: FP7-SME
Development of an oral Helicobacter Pylori vaccine [Print to PDF] [Print to RTF]
Total cost:EUR 1 809 000
EU contribution:EUR 1 303 000
Topic(s):SME-2012-1 - Research for SMEs
Call for proposal:FP7-SME-2012
Funding scheme:BSG-SME - Research for SMEs
"Helicobacter pylori infection is highly prevalent worldwide and is an important cause of gastritis, peptic ulcer disease, and significantly gastric cancer. Because eradication requires treatment with multidrug regimens, there exists a very strong need for a vaccine to prevent initial infection.
Immunization with H pylori protein subunits in humans has shown adjuvant-related adverse effects and only moderate effectiveness. However, with much greater knowledge of the molecular basis of infection and having learnt lessons from previous vaccine developments, the current consortium have drawn together three strand that are considered critical to the development of an effective vaccine:
- Powerful, safe and multivalent antigens
- Powerful, safe and multi-acting adjuvants
- Powerful, modular and flexible oral vaccine delivery system
All three of the above innovative technologies have been proven to be effective in doing what they are required to do, namely:
- Antigens – produce antibodies against a number of key H pylori bacterial components
- Adjuvants – stimulate the immune cells to produce significant numbers of long lasting antibodies
- Delivery – formulate antigens and adjuvants together and target the stomach and intestine
This consortium (HELICOVAXOR) uniquely converges all three into a true vaccine with real potential to protect from H pylori infection. The vaccine is being designed for oral administration, efficacy, safety and temperature stability.
This consortium has assembled leading academic, industrial and regulatory groups, the activities of which will be coordinated to perform analysis of the formulations, efficacy and safety testing of the vaccines and the preparation of a regulatory dossier, all required before the product can enter human clinical studies.
If successful in pre-clinical studies, the consortium will work with vaccine companies to progress human studies and launch the product as a vaccine to confer protection from H pylori infection."
EU contribution: EUR 1 169 500
"THE INVENT CENTRE, DUBLIN CITY UNIVERSITY"
EU contribution: EUR 25 000
VASTRA FROLUNDA, Sweden
Tel.: +46 3 17866200
EU contribution: EUR 108 500
Via della Posta 10
Tel.: +41 91 610 7000
Tel.: +353 1 834 3905
Tel.: +353 1 8205395
CRAIGAVON, United Kingdom
Tel.: +44 28 3833 2200
Fax: +44 2838332299
HARLOW, United Kingdom
Tel.: +44 1 279 441616
Tel.: +46 31 7866470
Tel.: +41 61 906 59 59
KONAROVICE, Czech Republic
Tel.: +420 313 129 374 5